Unlocking the potential of
genomic medicine


Download Documentation Aevi Genomics Investor Presentation

Aevi Genomic Medicine is focused on translating genetic discoveries into novel therapies to improve the lives of children and adults with pediatric onset life altering diseases.  More >>
Stock Quote
GNMX (Common Stock)
PriceChange% ChangeVolume
$1.24 - 0.043.13%185,488
Previous CloseToday's OpenIntraday HighIntraday Low
Exchange: NASDAQ (US Dollar)
05/25/17 1:55 p.m. ET
Refresh quote
2016 Annual Meeting Materials

Annual Report to Stockholders
Proxy Statement
Proxy Card

Recent NewsMore >>
05/10/17Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001 and First Quarter 2017 Operating Results
PHILADELPHIA, PA -- (Marketwired) -- 05/10/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) Company to initiate a Phase 2 clinical trial in 2H 2017, targeting a specific genetic subset of patients identified by a responder analysis of the SAGA trial Responder subset is approximately 10% of the US pediatric ADHD population and a total addressable market of $2 to $3 billion Genetic subset had a 90% response rate and stimulant-like effect in the SAGA t... 
Printer Friendly Version
05/03/17Aevi Genomic Medicine to Host Conference Call to Announce First Quarter and Discuss Recent Business Updates
PHILADELPHIA, PA -- (Marketwired) -- 05/03/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today it will host a conference call and live audio webcast on Wednesday, May 10, 2017 at 8:30 a.m. EDT to report financial results for the first quarter and discuss recent business updates. In order to participate in the conference call, please dial (888) 481-2845 (domestic) or (719) 325-2327 (international). The conference passcode is 9118660. The live webcast can be accessed... 
Printer Friendly Version
04/27/17Aevi Genomic Medicine to Present at the 42nd Annual Deutsche Bank Health Care Conference
PHILADELPHIA, PA -- (Marketwired) -- 04/27/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola, President and Chief Executive Officer, will present at the 42nd Annual Deutsche Bank Health Care Conference on Thursday, May 4, 2017 at 1:10 p.m. EDT at the InterContinental Boston Hotel in Boston, MA. A live webcast of the presentation can be accessed under "Presentations" in the Investors section of the Company's website at www.aevigenomics.com or y... 
Printer Friendly Version
Recent PresentationsMore >>
Download Documentation Q1 2017 Aevi Genomic Medicine Earnings Presentation
Download Documentation Deutsche Bank 42nd Annual Health Care Conference
Download Documentation Aevi Genomic Medicine Poster Presentation at the 6th World Congress on ADHD: Double-Blind, Placebo-Controlled Study of the Novel Therapeutic AEVI-001 in Adolescents with ADHD and Glutamatergic Network Gene Mutations
Download Documentation Aevi Genomic Medicine Poster Presentation at the 6th World Congress on ADHD: Glutamatergic Network Gene Mutations in Children and Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
Download Documentation SAGA Trial of AEVI-001 Top-line Results Presentation
Download Documentation Aevi Genomics Cowen & Co. 37th Annual Health Care Conference Presentation
Download Documentation Aevi Genomics Investor Day Presentation
Download Documentation JP Morgan 2017 Presentation
Download Documentation Medgenics Inc at the 28th Annual Piper Jaffray Healthcare Conference
Download Documentation Q3 2016 Medgenics Inc Earnings Presentation
Download Documentation Medgenics Poster Presentation at the 63rd Annual American Academy of Child & Adolescent Psychiatry
Download Documentation Q2 2016 Medgenics Inc Earnings Presentation
Download Documentation JMP Life Sciences Conference
Download Documentation Medgenics / Kyowa Hakko Kirin Collaboration for Severe Pediatric Onset Inflammatory Bowel Disease
Download Documentation Medgenics Inc at UBS Global Healthcare Conference Presentation
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Aevi Genomic Medicine, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed.